Chalk up another strike against Big Tobacco. For a change, however, it isn't domestic tobacco producers that are on the defensive but global companies that could be facing a whirlwind of change if Russia, the world's third-largest tobacco market, is successful in implementing stringent anti-smoking laws.
Passed by Russian President Vladimir Putin in February and going into effect yesterday, new regulations ban smoking at schools and universities, in hospitals, sports facilities, and museums, and on public transportation. Smoking is predominantly banned in these areas already, but this is more of a uniform countrywide ban, as Reuters notes.
Source: MoneyBlogNews on Flickr.�
The real challenge is coming up next year, when the smoking contingencies widen to include a ban in cafes, restaurants, hotels, and street kiosks and will set a minimum countrywide price on a pack of cigarettes. Outside of mandating a new minimum price that would certainly be much higher than the current price, this is sounding awfully familiar to some of the policies enacted by California and the city of New York.
Top 10 Defensive Stocks To Buy Right Now: Guggenheim CurrencyShares Canadian Dollar Trust (FXC)
Guggenheim CurrencyShares Canadian Dollar Trust, formerly CurrencyShares Canadian Dollar Trust, is a grantor trust. The Trust issues shares (the Shares) in blocks of 50,000 (a Basket) in exchange for deposits of Canadian dollars and distributes Canadian dollars in connection with the redemption of Baskets. The investment objective of the Trust is for the Shares to reflect the price of Canadian Dollars. The Bank of New York Mellon serves as the Trustee. The Trust�� sponsor is Rydex Specialized Products LLC, which is doing business as Rydex Investments.
The Shares are focused on offering investors an opportunity to participate in the market for the Canadian Dollar through an investment in securities. The Shares are backed by the assets of the Trust, which does not hold or use derivative products. The Trust�� each outstanding Share represents a proportional interest in the Canadian dollars held by the Trust. The Trust�� assets primarily consist of Canadian dollars on demand deposit in two deposit accounts maintained by JPMorgan Chase Bank N.A. (the Depository): a primary deposit account, which may earn interest, and a secondary deposit account that does not earn interest.
Advisors' Opinion:- [By Dan Caplinger]
One of the primary worries that would-be Bitcoin users have about digital currency is that its existence relies on computer networks beyond their control. By contrast, existing currency and commodity ETFs can in many cases point to actual physical assets. SPDR Gold Trust (NYSEMKT: GLD ) and iShares Silver Trust (NYSEMKT: SLV ) , for instance, publish lists of physical bullion bars to support the underlying value of their shares. Currency ETFs CurrencyShares Canadian Dollar (NYSEMKT: FXC ) and CurrencyShares Japanese Yen (NYSEMKT: FXY ) usually turn to short-term investments denominated in their respective currencies.�
Top 10 Defensive Stocks To Buy Right Now: Goodrich Petroleum Corporation (GDP)
Goodrich Petroleum Corporation, an independent oil and natural gas company, engages in the exploration, development, and production of oil and natural gas. The company holds interest in the Eagle Ford Shale Trend located in South Texas; the Haynesville Shale and Cotton Valley Taylor Sand in northwest Louisiana and East Texas; and the Tuscaloosa Marine Shale located in southwest Mississippi and southeast Louisiana. It owns working interests in 392 producing oil and natural gas wells located in 32 fields in 8 states. As of December 31, 2012, the company had estimated proved reserves of approximately 254.0 billion cubic feet of natural gas, 5.1 million barrels of crude oil or other liquid hydrocarbons (MMBbls) of natural gas liquids, and 8.1 MMBbls of oil and condensate. Goodrich Petroleum Corporation was founded in 1995 and is based in Houston, Texas.
Advisors' Opinion:- [By Canadian Value]
It seems the market has been placing too much emphasis on China�� short-term economic data releases. In September, the economic data flow failed to sustain the very buoyant signals seen in July and August. Export data were somewhat softer, while industrial production and fixed asset investment growth slowed a little. Toward the end of October, once again, the People�� Bank of China chose not to inject liquidity to ease a seasonal tightening in interbank liquidity, and Chinese interbank lending rates moved higher, which also served to dampen market sentiment. However, domestic consumption remained buoyant, while data on power consumption and metal imports suggested that activity remained elevated. China�� third-quarter gross domestic product (GDP) growth at 7.8% year-on-year showed an acceleration on the second-quarter pace.
Top 5 Restaurant Stocks To Buy Right Now: GlaxoSmithKline PLC(GSK)
GlaxoSmithKline plc, together with its subsidiaries, engages in the discovery, development, manufacture, and marketing of pharmaceutical products, over the counter (OTC) medicines, and health-related consumer products worldwide. It offers pharmaceutical products in various therapeutic areas comprising respiratory, HIV, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, oncology and emesis, vaccines, and dermatologicals. The company provides prescription medicines to treat a range of conditions, including infections, depression, skin conditions, asthma, heart and circulatory disease, and cancer. It also markets a range of vaccines to prevent life-threatening or crippling illnesses, such as hepatitis A, hepatitis B, diphtheria, tetanus, whooping cough, measles, mumps, rubella, polio, typhoid, influenza, and bacterial meningitis. In addition, the company provides OTC medicines, including Panadol, a paracetamol-based treatment of headache and joi nt pain, fever, and cold symptoms; Gaviscon, a range of antacid products that relieve heartburn due to acid reflux; and NicoDerm, NiQuitin CQ, Nicabate, and Nicorette for the treatment of nicotine withdrawal as an aid to quit smoking. Further, it offers oral healthcare products comprising Sensodyne, a range of toothpastes and toothbrushes for the prevention of dental sensitivity; Aquafresh, a range of toothpastes, toothbrushes, and mouthwashes; and Polident, Poligrip, and Corega, which are denture adhesives and cleansers. Additionally, the company provides nutritional healthcare products consisting of Lucozade, an energy and sports drinks for energy and hydration; Horlicks, a malted, milk-based drink and food for nutrition application; and Ribena, an apple, orange, raspberry, and pomegranate flavored fruit drink, as well as markets skincare products. GlaxoSmithKline plc was incorporated in 1999 and is headquartered in Brentford, United Kingdom.
Advisors' Opinion:- [By Sean Williams]
The best and most obvious solution here is to wear protective sunscreen and reduce your exposure to the sun to a moderate level. If a person is already well beyond that stage, two newly approved melanoma drugs from GlaxoSmithKline (NYSE: GSK ) may ultimately be called upon to do the trick. The drugs, Tafinlar and Mekinist, target the most common type of skin cancer that expresses the BRAF mutation. In trials, progression-free survival of the combo improved to 9.4 months, compared with 5.8 months for those taking Tafinlar by itself, with a whopping 41% of patients not exhibiting any signs of disease progression at 12 months!
- [By Keith Speights]
The FDA could take a cautious stance and opt against an accelerated pathway for eteplirsen. Another experimental DMD drug -- drisapersen from GlaxoSmithKline (NYSE: GSK ) �-- reportedly resulted in patients experiencing kidney toxicity. Last quarter, Garabedian alluded to possible FDA concerns about this safety issue, but he shrugged off any worries about eteplirsen producing similar effects.
Top 10 Defensive Stocks To Buy Right Now: Goldsearch Ltd (GSE)
Goldsearch Limited (Goldsearch) is an Australia-based minerals company. During the fiscal year ended June 30, 2012 (fiscal 2012), the Company was engaged in the exploration of gold and other minerals and investment activities. It operates in five segments: Mineral Exploration Sweden, Minerals Exploration Australia-Victoria, Minerals Exploration Australia-Other, Investments and Administration. Its other projects include the Mary Kathleen joint venture in Queensland and the Musgrave joint venture in South Australia. It held 16,000 square kilometres of tenements within the Musgrave Ranges of northwestern South Australia that were in joint venture between Goldsearch and Independence Group. During fiscal 2012, the Company held investments in Morning Star Gold NL (MCO) and Musgrave Minerals Ltd (MGV). On June 30, 2012, the Company had sold off its total investment in Independence Group NL (IGO). Its subsidiaries include: Caytale Pty Limited, Chiljill Pty Limited and Miltonpak Pty Limited. Advisors' Opinion:- [By Roberto Pedone]
Another environmental services player that looks ready to trigger a near-term breakout trade is GSE Holdings (GSE), which provides geosynthetic containment solutions for environmental protection and confinement applications. This stock has been hammered by the bears so far in 2013, with shares down big by 55%.
If you take a look at the chart for GSE Holdings, you'll notice that this stock recently ripped sharply higher back above its 50-day moving average of $2.32 a share with heavy upside volume. Following that move, shares of GSE have started to trend sideways between $2.60 on the downside and $2.95 on the upside. Shares of GSE are now starting to move within range of triggering a near-term breakout trade above the upper-end of its recent range.
Traders should now look for long-biased trades in GSE if it manages to break out above some near-term overhead resistance levels at $2.79 to $2.95 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 221,545 shares. If that breakout hits soon, then GSE will set up to re-test or possibly take out its next major overhead resistance levels at $3.50 to $4 a share.
Traders can look to buy GSE off any weakness to anticipate that breakout and simply use a stop that sits right below support at $2.60 or below its 50-day moving average at $2.32 a share. One could also buy GSE off strength once it takes out those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.
Top 10 Defensive Stocks To Buy Right Now: Prosensa Holding NV (RNA)
Prosensa Holding N.V., formerly Prosensa Holding B.V., is a biotechnology company engaged in the discovery and development of ribonucleic acid-modulating (RNA)-modulating, therapeutics for the treatment of genetic disorders. The Company�� primary focus is on rare neuromuscular and neurodegenerative disorders with a large unmet medical need, including Duchenne muscular dystrophy, myotonic dystrophy and Huntington�� disease. The Company�� clinical portfolio of RNA-based product candidates is focused on the treatment of Duchenne muscular dystrophy (DMD). The Company�� platform technology allows the development of RNA-modulating therapeutics that either interferes with splicing (exon skipping, exon inclusion, or splice mutation correction), remove mutant RNA, or block RNA expression, for different indications.
DMD is a rare, severe muscle wasting disease that occurs in up to 1 in 3,500 male births. It is commonly diagnosed between the ages of three to five, when boys begin to show signs of impaired motor development. PRO044, the Company�� product candidate, addresses a separate sub-population of DMD patients. The Company developed PRO044 using its exon-skipping technology to generate a product candidate with the same mechanism of action that is used by drisapersen.
Advisors' Opinion:- [By Leo Sun]
However, these three biotech stocks -- Amarin (NASDAQ: AMRN ) , Dendreon (NASDAQ: DNDN ) , Prosensa (NASDAQ: RNA ) -- don't fit that category at all. Read on to understand why these dogs of the sector should never be mistaken as underdogs.
- [By Keith Speights]
Successful launch
You couldn't even buy stock in Prosensa (NASDAQ: RNA ) just a few weeks ago. The biotech launched its IPO on June 28. To say that launch has gone successfully is an understatement. Shares are now more than double the IPO price and climbed 41% this week. - [By Sean Williams]
What: Shares of Prosensa (NASDAQ: RNA ) , a clinical-stage developer of RNA-modulating therapeutic agents for genetic disorders, jumped as much as 50% after reporting additional clinical findings on drisapersen at the JPMorgan Healthcare Conference.
- [By Keith Speights]
An "alley-oop" from the opponent
Prosensa (NASDAQ: RNA ) shares made something of a slam dunk this week, jumping more than 16%. That dunk was made with what amounts to an "alley-oop" from its primary rival, Sarepta Therapeutics (NASDAQ: SRPT ) .
Top 10 Defensive Stocks To Buy Right Now: Oxygen Biotherapeutics Inc.(OXBT)
Oxygen Biotherapeutics, Inc., a development stage company, engages in developing biotechnology products that deliver oxygen to target tissues in the body in the United States. The company primarily offers Oxycyte, a perfluorcarbon (PFC) based oil in water emulsion that carries oxygen and is been formulated for intravenous delivery for the treatment of traumatic brain injury, spinal cord injury, and decompression sickness; and other PFC-based oxygen carriers for use in personal care, topical wound healing, and other topical indications. It also provides Dermacyte line of topical cosmetic products that promote the appearance of skin health and other cosmetic benefits; and Wundecyte, a wound-healing gel. It markets its Dermacyte line of products through buydermacyte.com; and to dermatologists and medical spas with a combination of in-house sales, independent sales agents, and distributors. The company was formerly known as Synthetic Blood International, Inc. and changed its n ame to Oxygen Biotherapeutics, Inc. in June 2008. Oxygen Biotherapeutics, Inc. was founded in 1967 and is based in Morrisville, North Carolina.
Advisors' Opinion:- [By Lauren Pollock]
Oxygen Biotherapeutics Inc.(OXBT) said it agreed to buy about $4.8 million in assets from Phyxius Pharma that treat cardiac-surgery patients. Shares of Oxygen Biotherapeutics rose.
- [By Paul Ausick]
Stocks on the Move: GT Advanced Technologies Inc. (NASDAQ: GTAT) is up 20.5% at $10.10 after earnings and signing deal to supply Apple Inc. (NASDAQ: AAPL) with sapphire glass. Marvell Technology Group Ltd. (NASDAQ: MRVL) is up 8.5% at $13.03 following reports of an investment by KKR & Co. (NYSE: KKR). Oxygen Biotherapeutics Inc. (NASDAQ: OXBT) is up 62.7% at $8.38 along with other biotech stocks making big moves today.
- [By John Udovich]
Yesterday, small cap Oxygen Biotherapeutics, Inc (NASDAQ: OXBT) surged 87.33% to $2.81 after published results showed that its levosimendan was associated with reduced mortality, meaning its probably time to do a reality check about the stock as well as look at its performance against that of industry benchmarks like the iShares NASDAQ Biotechnology Index ETF (NASDAQ: IBB) and SPDR S&P Biotech ETF (NYSEARCA: XBI).
- [By Bryan Murphy]
To say that Oxygen Biotherapeutics, Inc. (NASDAQ:OXBT) has made its presence known over the past three weeks would be an understatement. It would be more accurate and fairer to say OXBT been an "in your face" kind of name that you couldn't look past even if you wanted to. Rather than continue to sidestep it, care to stop, invest two minutes of time, and get the Q&D version of what's really going on here? If so, read on.
Top 10 Defensive Stocks To Buy Right Now: Shenandoah Telecommunications Co(SHEN)
Shenandoah Telecommunications Company, a diversified telecommunications company, provides regulated and unregulated telecommunications services to end-user customers and other communications providers in the southeastern United States. It offers a suite of voice, video, and data communications services; and sells telecommunications equipment. The company?s Wireless segment provides digital wireless service to a portion of a four-state area covering the region from Harrisburg, York, and Altoona, Pennsylvania to Harrisonburg, Virginia. It owns 149 towers and leases tower space to other wireless communications providers in Virginia, West Virginia, Maryland, and Pennsylvania. This segment also offers personal communications services through a digital wireless telephone and data network. Its Wireline segment provides regulated and unregulated telephone services and leases fiber optic facilities primarily in the northern Shenandoah Valley. This segment also offers information s ervices and Internet access to customers in the northern Shenandoah Valley and surrounding areas. In addition, it is involved in the resale of long distance service for calls placed to locations outside the regulated telephone service area by telephone customers. As of December 31, 2011, this segment had approximately 1,410 dial-up customers and 12,351 digital subscriber line customers, as well as served approximately 10,483 long distance customers. The company?s Cable Television segment provides coaxial cable-based television service in the portions of Shenandoah County, Virginia, as well as in communities in West Virginia, southern and southwestern Virginia, and western Maryland. It had approximately 137,238 cable revenue generating units. The company was founded in 1902 and is headquartered in Edinburg, Virginia.
Advisors' Opinion:- [By Jake L'Ecuyer]
Leading and Lagging Sectors
Wednesday morning, the healthcare sector proved to be a source of strength for the market. Leading the sector was strength from Horizon Pharma (NASDAQ: HZNP) and Pernix Therapeutics Holdings (NASDAQ: PTX). In trading on Wednesday, telecommunications services shares were relative laggards, down on the day by about 0.39 percent. Top decliners in the sector included Shenandoah Telecommunications Co (NASDAQ: SHEN), off 3.3 percent, and CalAmp (NASDAQ: CAMP), down around 2.4 percent.
Top 10 Defensive Stocks To Buy Right Now: Sarepta Therapeutics Inc (SRPT)
Sarepta Therapeutics Inc., formerly AVI BioPharma, Inc., incorporated on July 22, 1980, biopharmaceutical company focused on the discovery and development of ribonucleic acid (RNA)-based therapeutics for the treatment of rare and infectious diseases. The Company�� product candidates include Eteplirsen, AVI-6002, AVI-6003, and AVI-7100. As of December 31, 2011, the Company primarily focused on advancing the development of its Duchenne muscular dystrophy drug candidates, including its lead product candidate, eteplirsen, which is in a Phase IIb trial. The Company is also focused on developing therapeutics for the treatment of infectious diseases, including its lead infectious disease programs aimed at the development of drug candidates for the Ebola and Marburg hemorrhagic fever viruses. The Company's program focuses on the development of disease-modifying therapeutic candidates for Duchenne muscular dystrophy (DMD). The Company initiated a Phase IIb trial for eteplirsen in August 2011 with an objective of initiating a pivotal trial subsequent to 2011.
The Company is also leveraging the capabilities of its RNA-based technology platforms to develop therapeutics for the treatment of infectious diseases. The Company's RNA-based drug programs are clinically evaluated for the treatment of DMD and have also demonstrated anti-viral activity in infectious diseases such as Ebola, Marburg and H1N1 influenza in certain animal models. The Company's lead product candidates are at various stages of development.
Duchenne Muscular Dystrophy Program
The Company's lead program is designed to address specific gene mutations that result in DMD by forcing the genetic machinery to skip over an adjacent contiguous piece of RNA and, thus, restore the ability of the cell to express a new, truncated but functional, dystrophin protein.
Eteplirsen is an antisense PMO-based therapeutic in clinical development for the treatment of individuals with DMD who have an error in the gene codi! ng for dystrophin that can be treated by skipping exon 51. Eteplirsen targets the frequent series of mutations that cause DMD. Eteplirsen has been granted orphan drug designation in the United States and European Union. In addition to the Company's lead product candidate, eteplirsen, the Company is actively pursues development of a product candidate that skips exon 45 through an IND-enabling collaboration.
Anti-Viral Programs
The Company is implementing its RNA-based technology platforms in its anti-viral programs for the development of therapeutics to treat viruses, such as Ebola, Marburg and influenza. The Company's arrangement with DoD supporting the development of the Company's Ebola and Marburg virus drug candidates provides funding for all clinical and licensure activities necessary to obtain approval of a New Drug Application (NDA), by the United States Food and Drug Administration (FDA), if DoD exercises all of its options under the arrangement. During the year ended December 31, 2011, the Company paused its clinical development efforts on AVI-7100 and is exploring funding opportunities or partnerships with DHHS and industry collaborators to advance its development.
The Company's anti-viral therapeutic programs use the Company's translation suppression technology and applies its PMOplus chemistry backbone, an advanced generation of its base PMO chemistry backbone that selectively introduces positive backbone charges to improve selective interaction between the drug and its target. The Company's translation suppressing technology is based on Translation Suppressing Oligomers (TSOs), which are PMO-based compounds that stop or suppress the translation of a specific protein by binding to their specific target sequence in mRNA.
The Company is pursuing development and regulatory approval of its Ebola and Marburg hemorrhagic fever virus product candidates under the FDA's Animal Rule. The Company's lead product candidate against the Ebola virus infec! tion is A! VI-6002. For Marburg virus infection, the Company's lead product candidate has been AVI-6003. In February 2012, the Company announced that the Company received approval from the FDA to remove one of the two oligomers composing AVI-6003 and proceed with a single oligomer approach, AVI-7288, given that efficacy in non-human primates has been demonstrated to be attributable to this single oligomer. The Company is exploring the feasibility of alternate routes of administration of its Ebola and Marburg drug candidates, and at DoD's invitation, the Company is developing a proposal to be submitted for a study to demonstrates feasibility of the intramuscular route.
AVI-6002, which is a combination of AVI-7537 and AVI-7539, is designed for post-exposure prophylaxis after documented or suspected exposure to the Ebola virus. The Company is evaluating the feasibility of developing AVI-7537 as a single agent for the post-exposure prophylaxis after documented or suspected exposure to Ebola virus. AVI-6003, which is a combination of AVI-7287 and AVI-7288, is designed for post-exposure prophylaxis after documented or suspected exposure to Marburg virus. In February 2012, the Company announced that the Company received approval from the FDA to proceed with AVI-7288 as a single agent against Marburg virus infection. The Company intends to proceed with dosing AVI-7288 in the Phase I multiple ascending dose studies and in non-human primate studies.
Influenza Program
The Company's anti-viral therapeutic programs are also focused on the development of the Company's product candidates designed to treat pandemic influenza viruses. AVI-7100 is the Company's lead product candidate for the treatment of influenza and employs its PMOplus technology. In June 2011, the Company initiated dosing of AVI-7100 through intravenous infusion in single-ascending doses in up to 48 healthy adult volunteers. As of December 31, 2011, the Company paused its clinical development efforts on AVI-7100 and are exp! loring fu! nding opportunities or partnerships to advance its development.
The Company has developed three new phosphorodiamidate-linked morpholino oligomers (PMO)-based chemistry platforms in addition to its original PMO-based technology. The Company's PMO-based molecules are designed to sterically block the access of cellular machinery to pre-mRNA and mRNA without degrading the RNA. Through this selective targeting, two distinct biologic mechanisms of action can be initiated: modulation of pre-mRNA splicing and inhibition of mRNA translation.
The Company competes with GlaxoSmithKline plc, Toyama Chemical, Alnylam Pharmaceuticals, Inc., Tekmira Pharmaceuticals Corp., Isis Pharmaceuticals, Inc., Prosensa, and Santaris Pharma A/S.
Advisors' Opinion:- [By Keith Speights]
Sarepta Therapeutics (NASDAQ: SRPT ) �won't be the only stock choice for a biotech focusing on Duchenne muscular dystrophy, or DMD, much longer.� Its one potential challenger on the scene, Prosensa, recently announced plans to move forward with an initial public offering. Here are three views on what a Prosensa IPO could mean for Sarepta.
- [By Ernie Tremblay, Biosciences Specialist, Money Morning | January 17, 2014 · ]
When I'm setting out in search of a lucrative bioscience stock, here are some qualities I find really attractive:
Market cap. $250M-$2.5B. This is the sweet spot for growth. Less than $250M can mean low volume trading, which can be a problem if you need to sell. More than $2.5B makes a company less responsive to catalysts. Single product pipeline. These companies can yield high returns because they carry high risk. If their drug succeeds, their investors can get rich rapidly. A failure, however, can mean doom, so you need to know what you're doing in evaluating the drug's potential to be effective, safe, convincing to the FDA, and marketable. Some of my recommendations, of course, are for companies that have richer pipelines. They yield less return, but they're safer bets for a balanced portfolio. An upcoming catalyst. A catalyst, such as an AdCom, FDA approval date (called a PDUFA), or even results from a clinical trial, can make you a whole lot richer overnight. Last year, Sarepta Therapeutics (Nasdaq: SRPT) tripled its stock price overnight when the company announced positive results for a study of its Duchenne muscular dystrophy drug. Orphan drug status. As I explained above, these drug candidates have real advantages over traditional "blockbuster" entries. An extreme need. Everyone born with HoFH would eventually die from it, and before Aegerion's Juxtapid (lomitapide), no effective treatment existed. Patients were longing for it. Little or no competition. ISIS Pharmaceuticals Inc. (Nasdaq: ISIS), in partnership with Genzyme Pharmaceuticals, was developing a drug, mimoperson, to compete with Juxtapid, but it was inferior in several ways (injectable rather than oral, more severe side effects). It also passed its AdCom, but barely, garnering a vote of 9 to 6. Juxtapid had a nearly clear field to play in. The Profits AheadNext, of course, comes the tricky part. You've got to be able to read studies on exper
- [By Jake L'Ecuyer]
Shares of Sarepta Therapeutics (NASDAQ: SRPT) gained 8.03 percent to $17.83 after WBB Securities rated the company with a Speculative Buy while bumping its price target to $19.
Top 10 Defensive Stocks To Buy Right Now: PDL BioPharma Inc.(PDLI)
PDL BioPharma, Inc. engages in intellectual property asset management and royalty bearing assets investment activities. The company is involved in the humanization of monoclonal antibodies and the discovery of a new generation of targeted treatments for cancer and immunologic diseases. It offers Queen et al. patents that cover humanized antibodies, methods for humanizing antibodies, polynucleotide encoding in humanized antibodies, and methods of producing humanized antibodies. The company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006. PDL BioPharma, Inc. was founded in 1986 and is headquartered in Incline Village, Nevada.
Advisors' Opinion:- [By Brian Orelli]
PDL BioPharma (NASDAQ: PDLI ) did much better with the spin out of its development stage program into Facet Biotech. The biotech started trading at $13�per share, and was eventually taken out by Abbott for $27. The main assets now reside in Abbott's aforementioned spinout AbbVie in conjunction with Biogen Idec, which was developing the drugs with PDL. If the drugs are successful, maybe the duo will spin them out into a joint venture, completing the cycle?
Top 10 Defensive Stocks To Buy Right Now: Neutra Corp (NTRR)
Neutra Corp. incorporated on January 11, 2011, is a development-stage company. The Company�� business and registered office is located in Sarasota, Florida. The Company�� intended private label products consists of aging, cognitive support, antioxidants/flavonoids, circulatory support, detoxification support, endocrine support, essential fatty acids, gastrointestinal support, immune support, men�� health, minerals, mood/sleep support, multiples, musculoskeletal support, neurological support, proteins/amino acids, vitamins, women�� health and veterinary products. The Company�� product focuses to research and development in a range of areas, such as weight-loss, detox, men�� health, acid-alkali pH balance, anti-aging, sleep disorders, autism, pain management with the use of medical cannabis products, and air space sanitation derived by nutraceutical technology.
The Company focuses to market and sell nutraceutical supplement products to health practitioners. It focuses direct marketing and sales towards Members of the American Association for Health Freedom (American Association for Health Freedom has merged with Alliance for Natural Health) www.anh-usa.org; American Association of Naturopathic Physicians, www.naturopathic.org; American Association of Oriental Medicine, www.aaom.org, and American College for Advancement in Medicine, www.acamnet.org. It also focuses direct marketing and sales towards American Holistic Medical Association, www.holisticmedicine.org; American Dietetic Association, www.eatright.org, and American Herbalist Guild, www.americanherbalistsguild.com.
The Company competes with Thone Research, The Vitamin Company, Nutraceutical International Corporation, Protocol For Life, Medagenics and Standard Process.
Advisors' Opinion:- [By CRWE]
Today, NTRR has shed (-5.26%) down -0.020 at $.360 with 14,150 shares in play thus far (ref. google finance Delayed: 10:46AM EDT July 3, 2013), but don�� let this get you down.
Neutra Corp. through a key new partnership with an innovative cannabis delivery systems provider in the medical marijuana industry, is poised to make an impact in the lucrative $52 billion pain management market.
With partner Field of View Technologies, LLC, exploring new technology in cannabis delivery systems, NTRR is ready to provide much-needed smokeless delivery systems to those most in need: patients forced to live with debilitating pain.
A recent study by Columbia University found that smoke-free cannabinoid medication was effective in treating pain. Smokeless delivery systems can be administered orally, by injection or topically, giving the patient the choice of treatment method as NTRR and Field of View set the pace in the potentially lucrative pain management market.
No comments:
Post a Comment